Stem Cell Use:
Embryonic Stem Cell
Cell Line Generation:
Embryonic Stem Cell
n therapeutic cloning, a patient’s cell is combined (fused) to an enucleated donated egg (oocyte) from an unrelated woman or from another animal. It is hoped that cellular factors in the egg cytoplasm will reprogram the patient’s cell nucleus making it capable of generating replacement cells for the patient’s body. Thus, if a patient is suffering from Parkinson Disease due to loss of brain cells, these cells could be replaced with differentiated, individualized, nuclear-transplantation, embryonic stem (ntES) cells. While this strategy should generate ntES cells with the patient’s nuclear DNA (nDNA), it overlooks the fact that another part of the cell, the mitochondrion, also has DNA, the mitochondrial DNA (mtDNA). While the nDNA contains the blueprints for assembling the structure of the cell and body, analogous to carpenter’s plans for a house; the mtDNA contains the blueprints for the cellular electrical system, the wiring diagram of the house. It is universally agreed that mixing the nDNAs from two different cells would be destructive, yet the potentially disastrous effects of mixing different mtDNAs has been overlooked. In electricity, randomly mixing the components of two different integrated electrical circuits will result in short circuits. The same appears to be true for the cell. In mice in which we artificially mixed two mtDNAs, the resulting mice aged and died prematurely, had a striking increased frequency of cancer, and an increased mtDNA mutation rate. Moreover, in human studies, the accumulation of mtDNA mutations has been associated with aging and the development of cancer. Therefore, to document what happens to the mtDNAs during the creation and growth of htES and hES cells, we propose to create ntES cells by fusion of human cells to enucleated rabbit eggs and then to monitor the fate of the human and rabbit mtDNAs. We will also determine if the mitochondria and mtDNAs of hES cells can influence the differentiated state of tissue cells, investigate the nature and extent of mtDNA mutations that accumulate in ES cells, and determine if mixing different mtDNAs in cells is deleterious. Then we will determine the effects of these various mtDNA genetic factors on the power output of the mitochondria and its effects on the ES cell’s capacity to differentiate and potentially to form tumors. Finally, we propose to develop a series of procedures to control the origin and nature of the mtDNAs in ntES and hES cells and to use changes in mitochondrial function to regulate ntES and hES cell growth and regulation. It is our hope that by utilizing mitochondrial biology and genetics it may be possible to develop strategies for creating individualized stem cells without using donated oocytes.
Statement of Benefit to California:
Prolonged cell culture of human Embryonic Stem Cells (hESCs) frequently results in the loss of the cell’s capacity to differentiate on command into well differentiated cells. This eliminates their utility for generating replacement cells for use in cell replacement therapy to repair damaged tissues and organs within the body. The reason for this loss of developmental capacity by the hESCs is currently unclear, but we believe that a major factor contributing to the decline in the therapeutic value of hESCs is the accumulation of deleterious mutations in the mitochondrial DNA (mtDNA) of the cultured hESCs. The mtDNAs are located in the mitochondria which are organelles in the cytoplasm of the human cell. The mitochondria are responsible for generating most of the energy used by the cell and as a toxic by-product, the mitochondrial generate most of the endogenous reactive oxygen species (ROS). The mtDNA encodes key elements of the mitochondrial energy generating apparatus, and since ROS is a mutagen, the mtDNA is highly prone to acquiring mutations in these energy genes. These mutations then inhibit mitochondrial energy production which also results in increased ROS production. Increased mitochondrial ROS production stimulates the cell growth, so the cells with the mutant mtDNAs out grow the normal cells. However, the more rapidly growing cells with the mutant mtDNAs also have reduced mitochondrial energy production, which together with the increased ROS production, inhibits the developmental capacity of the hESC. In this research, we propose to establish that deleterious mtDNA mutations do in fact accumulate in hESCs over time and that they play an important role in the loss of the developmental potential of hESC cells. If we can confirm that this is a fact, then we should be able to greatly increase the therapeutic potential of hESCs by developing procedures for protecting the mtDNA of the hESCs from oxidative damage. This might be accomplished by growth of hESCs in the presence of mitochondrially target antioxidants. Furthermore, cells that had lost their developmental potential might be revitalized by simply replacing the damaged mtDNAs with good mtDNAs using our trans-mitochondrial cybrid technique. Thus, the proposed research has the potential of greatly increasing the therapeutic potential of all hESCs that will be developed in the State of California.
Our research is demonstrating that normal mitochondrial energy production is absolutely essential for the successful growth and differentiation of embryonic stem (ES) cells. Moreover, dysfunctional mitochondrial may also increase the potential to premature aging and cancerous growth of ES cells derived tissue cells. However, the biology of mitochondrial energy production in ES cells has been virtually ignored in ES cell studies. This oversight could have major negative consequences for the use of human ES cell-derived tissue therapeutics. Development involves the utilization of energy to build new cell and tissue structures. The genetic information to make structures is encoded by the nuclear DNA (nDNA) genes, but the information to generate energy by the mitochondria, the cellular power plants, is encoded by the maternally-inherited mitochondrial DNA (mtDNA) plus genes in the nDNA. The mtDNA is located in the cytoplasm within the mitochondia. Each cells contains hundreds of mitochondrial and thousands of mtDNAs. Therefore, to fully understand the biology and developmental potential of ES cells, we must understand the genetics and energetics of the ir mitochondria. To clarify the role of mitochondrial genes in ES cell biology, we have published a review summarizing all studies in which mouse ES (mES) cells which harbored deleterious nDNA or mtDNA mitochondrial gene mutations were used to generate mice. This revealed that mitochondrial defects had multiple deleterious consequences for both development and adult tissue function. This conclusion was confirmed by our creation of mice that harbored two mtDNAs, one with a severely deleterious mtDNA ND6 gene mutation linked to a milder COI mutation and the second mtDNA with only the COI mutation. Analysis of these mice revealed that the proto-oocytes of the female germline that harbored the severe mtDNA ND6 mutation were selectively and directionally eliminated from the female germline. Mice retaining the milded COI mutation developed a severe myopathy and cardiomyopathy. We also prepared and analyzed a mouse harboring two different but normal mtDNAs. Within these mice, one or the other mtDNA was selectively eliminated as he mice aged. Furthermore, animals with both mtDNAs showed a disturbance in circadian rhythms. Therefore, mtDNA variation is of paramount importance for normal development and even mild mtDNA mutations can have severe negative consequences in adults and their tissues. To extend these studies to human ES cells (hES), we have attempted to transfer hES cell mtDNAs into human somatic cells. These cell lines are being characterized. We have also attempted to introduce mutant mtDNAs into hES cells to evaluate the effects on their developmental potential. This requires elimination of the hES cell mtDNAs, for which we are evaluating different procedures. The mtDNAs that we hope to transfer to hES cells are chloramphenicol-resistance (CAPR) and the pathogenic tRNALeu(UUR) MELAS mutation. In addition, we have fused human cells harboring the CAPR to hES cells. We will continue the preparation and characterization of cell lines in which hES cell mtDNAs are transferred to somatic cells and vis-versa. To investigate the role of mitochondrial physiology on ES development, we prepared an extensive literature review on the mitochondrial regulation of the cellular biochemical pathways. We have developed a micro-chamber for assessing hES cell mitochondrial function. To assess whether mtDNA mutations would increase the tumorigenicity of ES cells, we have characterized the biochemical defect associated with a prostate cancer COI mtDNA mutation. We are also evaluating the cancer potential of our mice harboring the mtDNA COI mutation. To develop procedures for manipulating ES cell development by altering mitochondrial function, we have prepared a review on the role of mitochondrial physiology in regulating nDNA gene expression through modification of histones using mitochondrial high energy intermediates. To evaluate the effect of mitochondrial defects of differentiation, we have prepared a series of mouse muscle stem cell lines harboring related nDNA mitochondrial gene mutations and found marked changes in their developmental potential and physiology. We are also evaluating the physiological consequences of a human mtDNA variant found in Asian Americans in preparation for introducing it into hES cells. All of these studies have confirmed that energy biology has a profound effect of the developmental potential of ES cells.